Close Menu

NEW YORK – Bionano Genomics on Wednesday priced a $200 million underwritten public offering of its common stock that it announced the previous day.

The company plans to sell 33,333,350 shares of its common stock at a price of $6 per share, for an expected $200 million in gross proceeds. In addition, the underwriters have a 30-day option to purchase up to another 5,000,002 shares of common stock at the public offering price. The offering is expected to close on Jan. 22, subject to customary closing conditions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.